Purpose;To observe curative effect and side reaction

histopathology change of dose - dense combinated pharmorubicin with paclitaxel in advanced breast cancer treatment. Methods ;38 patients with advanced breast cancer diagnosed by pathology

which had e-valuation index

pharmorubicin 50mg/m2

d1

intravenous injection

paclitaxel 175mg/m2

d2

intravenous injection

every 2 weeks as 1 course of treatment

after accepted 2 - 4 course of treatment

all patients were evaluated. Results: All patients were followed up

clinical complete remission( CR) 10. 5%

clinical partial remission 71. 1%

total effective rate 81. 6% . effective rate in patents of initial treatment was much higher than that in patients of retreatmen; effective rate in patents of III stage also was much higher than that in patients of IV stage; low leucocyte and Neutropenia appeared III

IV side reaction

occupying respectively 63.2% and 71. 1% ;7.9% patients febricity owing to low leucocyte were cured by G - CSF and antibiotics

all patients successfully accomplish chemotherapy. Other side reaction

for instance thrombocytopenia.anaemia

nausea and vomiting etc

mostly displayed I

II toxic reaction

but they can be tolerated. After chemotherapy

cancer cells degeneration . cellular necrosis . retrogression and interstitial fibrosis .inflammatory cell infiltration are obviously changed. Conclusion: dose -dense chemotherapy combinated pharmorubicin with paclitaxel in advanced breast cancer treatment

remission rate was much higher and remission rate can be tolerated.